Brief: Evelo Biosciences Treats First Patients In Phase 2 Dose-Ranging Trial Of EDP1815
Oct 13 (Reuters) - Evelo Biosciences Inc EVLO.O :
* EVELO BIOSCIENCES TREATS FIRST PATIENTS IN PHASE 2
DOSE-RANGING
TRIAL OF EDP1815 FOR THE TREATMENT OF PSORIASIS
* EVELO BIOSCIENCES INC - INTERIM DATA FROM PHASE 2 TRIAL
EXPECTED
BY MID-2021
Source text for Eikon: ID:nGNX6sd65S
Further company coverage: EVLO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Evelo Biosciences
See all newsU.S. RESEARCH ROUNDUP- Evelo Biosciences, Nkarta, O'Reilly Automotive
U.S. STOCKS ON THE MOVE-DXC Technology, Nvidia, Lisata Therapeutics
Evelo Bio slumps after skin disease drug fails in mid-stage study
U.S. STOCKS ON THE MOVE-Nvidia, Westlake, North American steel companies
U.S. STOCKS ON THE MOVE-TMC, PayPal, TOMI